Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treosulfan - Medac

Drug Profile

Treosulfan - Medac

Alternative Names: CB 2562; CB 40067; CCRIS 2781; Dihydroxybusulphan; HSDB 6963; NSC 39069; Ovastat

Latest Information Update: 28 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medac
  • Developer Center for International Blood and Marrow Transplant Research; Fondazione San Raffaele; Medac
  • Class Antineoplastics; Butylene glycols; Mesylates; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Haematological malignancies; Haemoglobinopathies; Immunodeficiency disorders; Inborn error metabolic disorders; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Renal cell carcinoma; Small cell lung cancer; Solid tumours
  • Discontinued Malignant melanoma

Most Recent Events

  • 14 Dec 2018 Medac receives positive opinion from CHMP of the EMA for conditioning treatment prior to allogeneic haematopoietic stem cell transplantation
  • 12 Dec 2018 Fondazione San Raffaele and Medac complete the phase II TrRaMM4Gy trial in Haematological malignancies (In adults, In adolescents, In children, In infants) in Italy (EudraCT2011-001534-42)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top